Loading clinical trials...

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | Clinical Trials | Clareo Health

TERMINATEDPHASE1/PHASE2

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors

NCT00886782•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects with advanced and/or metastatic solid tumors who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist.
•ECOG performance status ≤ 2
•Accessible for treatment, PK sample collection and required study follow-up
•Total Bilirubin ≤ 1.5 x ULN and ALT, AST ≤ 2.5 x ULN

Exclusion Criteria

•Women who are pregnant or breastfeeding
•Subjects with known or suspected brain metastasis, primary brain tumors, or brain as the only site of disease
•Exposure to any investigational agent within 4 weeks of study drug administration
•Subjects a history of gastrointestinal disease

Locations (6)

Dana-Farber Cancer Institute-Vendor

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Local Institution - 003

Toronto, Ontario, Canada

Local Institution

Toronto, Ontario, Canada

Local Institution

Villejuif, France

Key Dates

Start Date

May 31, 2009

Primary Completion Date

August 4, 2010

Completion Date

August 4, 2010

Last Updated

April 28, 2023

Enrollment

ACTUAL participants

Conditions

Advanced Solid CancersMetastatic Cancer

Interventions

Cdc7-inhibitor

DRUG

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Advanced CancerMetastatic Cancer+7 more

View study

RECRUITINGPHASE1/PHASE2

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842

Advanced Solid Cancers

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors